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Abstract 
Purpose: This study was performed to elicit Chinese patients’ preferences for osteoporosis 
medication treatment and to investigate the heterogeneities of the preferences in subgroups. 
Methods: A discrete choice experiment comprising 15 choice sets with 4 important attributes 
was conducted in a Chinese population at risk of osteoporotic fracture. The four attributes 
were treatment efficacy in reducing the risk of fracture, out-of-pocket cost per year, adverse 
2 
 
effects of treatment, and mode of administration. The patients were asked to choose between 
two hypothetical treatments; they could also choose no treatment. Mixed logit models were 
used, and any observed heterogeneity in the patients’ preferences was further assessed in 
subgroup analyses. 
Results: In total, 267 patients were analysed. On average, the patients preferred to receive 
treatment rather than no treatment. The patients preferred treatment with higher efficacy in 
preventing fracture and lower out-of-pocket cost. The least preferred adverse effect of 
medication was gastrointestinal disorders, followed by flu-like symptoms and finally skin 
reactions. The most preferred mode of administration was annual intravenous infusion, 
followed by 6-month subcutaneous injection, a weekly oral tablet, and daily nasal spray; 
daily oral tablets ranked as the least preferred mode of administration. The differences in the 
patients’ preferences among all attributes were statistically significant (p<0.05). Patients’ age 
was found to contribute to the observed preference heterogeneity in most of the included 
attributes.  
Conclusions: This study revealed Chinese patients’ preferences for osteoporosis treatments. 
Annual intravenous infusion and 6-month subcutaneous injection were significantly preferred 
over weekly oral tablets in this Chinese population.  
 
Keywords: discrete choice experiment, pharmaceutical treatment, osteoporosis, patient 
preferences, Chinese 
 
Mini Abstract: 
While adherence to osteoporosis treatment is low, patients’ preference for osteoporosis 
treatment is unknown in Chinese patients.  Chinese patients are willing to receive treatments 
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with higher clinical efficacy and lower out-of-pocket cost. In addition, annual intravenous 
infusion and 6-month subcutaneous injection are preferred over weekly oral tablets.  
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Introduction 
Osteoporosis is defined by a bone mineral density (BMD) 2.5 standard deviation (SD) or 
more below the adult mean value, and patients with osteoporosis have a higher risk of 
fractures throughout their remaining life [1]. Pharmaceutical treatments of osteoporosis 
mainly focus on maintaining a healthy bone mineral density to reduce the risk of fragility 
fracture. While many medications are available to patients with a high risk of osteoporotic 
fractures (e.g., calcium, bisphosphonates, parathyroid hormone analogues, calcitonin receptor 
activator of nuclear factor kappa-B ligand inhibitors, oestrogen agonists, cathepsin K 
inhibitors, and monoclonal antibody to sclerostin), persistence and adherence to treatment 
continue to be a major concern [2]. Poor persistence and adherence to osteoporosis treatment 
not only jeopardizes the medication efficacy of preventing fracture [3] but also substantially 
reduces the cost-effectiveness of drug therapies [4, 5].  
Understanding the causes of poor adherence is therefore important. Although some 
intentional factors can contribute to poor medication adherence and persistence [6, 7], 
evidence has shown that interventions that using simplified dosing regimens, electronic 
prescription, patient decision aids, and patient education might improve osteoporosis 
medication persistence and adherence [8]. Understanding the patients’ needs and preferences 
and involving them in treatment decision-making could improve medication adherence [2].   
Discrete choice experiments (DCEs) are increasingly used to elicit patients’ preference for a 
health intervention based on the trade-offs among important attributes that might affect the 
patients’ behaviours in taking medications [9]. A few studies in Europe have investigated 
patients’ preferences for osteoporosis treatment. Despite converging evidence showing that 
patients had a preference for and were willing to trade among medications’ attributes, some 
differences in the most preferred level of each of the attributes were observed [10, 11]. For 
5 
 
example, in a cross-European DCE study, all patients in Belgium, France, Ireland, the 
Netherlands, Spain, Switzerland, and the United Kingdom expressed their preference for 
medications with lower out-of-pocket (OOP) costs and higher treatment efficacy [11]. With 
respect to the mode of administration, while 6-month subcutaneous injections was the most 
preferred mode in Belgium, Switzerland, Spain, and the United Kingdom, monthly oral 
tablets was the most preferred mode in France and the Netherlands [11]. Because of potential 
variations in patients’ preferences, application of the study results to other populations is 
limited. To our knowledge, no study has evaluated patients’ preferences for osteoporosis 
treatment in the Chinese population. Although osteoporotic fracture imposes dramatic disease 
and economic burdens onto Chinese society [12], persistence and adherence to osteoporosis 
treatment remains suboptimal [13]. Therefore, the present study was performed to gain 
insight into Chinese patients’ preferences for osteoporosis medication treatment. We also 
investigated the heterogeneity of the preferences in several subgroups of patients and 
compared Chinese patients’ preferences with European patients’ preferences. 
 
Methods 
Design of DCE 
The DCE questionnaire followed those used in previous European studies [10, 11]. The 
attributes included in the previous DCE were selected from patient interviews using the 
nominal group technique (NGT) [14, 15].  The NGT is a structured, multistep, facilitated group 
meeting technique used to elicit and prioritize responses to a specific question to prioritise health and 
healthcare problems [16]. The NGT has been shown feasible to select attributes in osteoporosis 
treatment DCEs [17].  Five focus groups from the Netherlands and Belgium participated in the 
interview. From an initial list of 12 potentially important attributes derived from the 
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literature, the focus groups revealed 4 important treatment attributes: effectiveness, adverse 
effects, mode of administration, and frequency of administration [15]. In addition, the OOP 
contribution was found to be important in Belgium, but it was not an important attribute in 
the Dutch population because there are no co-payments for medications in the Netherlands 
[15].  In line with the European DCE and after discussion/approval with Chinese clinicians 
(JG, AP, LT, YX, JL, QL, JQ, and ZL), we included the four most important attributes and 
combined the mode and frequency of administration as one attribute. In addition, because 
patients have co-payments and the amount of each co-payment depends on the type of service 
and health insurance [18], we also included OOP cost in this DCE. Finally, the four attributes 
evaluated in this study were the treatment efficacy in reducing the risk of fracture, OOP cost 
per year, adverse effects of treatment, and mode of administration (Table 1).   
<Table 1 should be inserted here> 
The experimental design was based on the characteristics of real osteoporosis medications 
that are currently used by Chinese patients including alendronate, zolendronic acid, 
raloxifene, calcitonin, denosumab and calcium/vitamin D3 [19, 20]. Calcium/vitamin D was 
the most commonly used drug followed by pain relievers, calcitonin and bisphosphonates in 
Chinese patients who sustained a fracture [19].  In addition, we aimed to design our DCE as 
close as possible to the European study for the sake of international comparison. The 
treatment efficacy in reducing the risk of fracture was determined based on the results of 
previous meta-analyses or clinical trials of common osteoporosis treatments [21-24]. The 
OOP cost per year was set according to the retail price of common osteoporosis medications 
at the Third Affiliated Hospital of Sun Yat-Sen University. For this question, patients were 
required to imagine to pay this amount themselves even if they were covered by health insurance and 
the medications might be fully or partially covered.  Adverse effects and modes of administration 
were also set based on current treatment using a literature review and expert opinion. To 
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construct the choice sets presented to the patients, a Bayesian efficient design was used to 
maximize the D-efficiency of the attributes using Ngene software (version 1.1.1, 
http://www.choice-metrics.com). The prior distributions for the Bayesian optimal design 
were taken from the European study [11]. 
Data collection 
In total, 15 choice sets were used for the DCE. In each choice set, the patients were asked to 
choose between two hypothetical medications (A and B) and indicate their preferred 
treatment option; a “no treatment” option was also available. An example of an English-
translated question is shown in Figure 1.  
<Figure 1 should be inserted here> 
The following patient demographic and socioeconomic data were collected: age, sex, 
education level, family income, weight, height, self-reported diagnosis of osteoporosis, bone 
mineral density, and previous clinical fracture. Living standard was measured by the per-
adult household income, which was calculated by the annual household income per annum 
divided by the number of adult equivalents [25]. 
Patient recruitment 
Convenience sampling was used to recruit study participants. Patients who attended the 
Department of Rheumatology of the Third Affiliated Hospital of Sun Yat-Sen University 
were assessed by the clinician on their risk of osteoporotic fracture. In this study, the 
inclusion criteria of study participants were as follows: 1) patients who were at risk of 
osteoporotic fracture; 2) patients who were willing to participate in our study. The paper-
based survey was supervised by a senior rheumatologist (JG) and was conducted by the 
onsite clinicians (LT, YX, JL, QL, JQ, and ZL). The study participants were provided with a 
thorough description of the questions before the survey and were given further assistance to 
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promote an understanding of the questions during the survey if needed. We have targeted to 
recruit 300 patients in our DCE given the common rules-of-thumb for minimum sample size in DCE 
and our experience in the European study [11, 26].  Patient recruitment was conducted from July 
2017 to June 2018. All participants provided written informed consent. The study was 
approved by the Sun Yat-Sen University Ethics Committee.  
Statistical analysis 
The data were analysed using a mixed logit model [27] based on the random utility theory, 
wherein the utility that respondent 𝑖 derives from choosing alternative 𝑗 in choice set 𝑡 is 
given by  
𝑈𝑖𝑗𝑡 = 𝑋𝑖𝑗𝑡𝛽𝑖 + 𝜀𝑖𝑗𝑡;   𝑖 = 1, … , 𝑛; 𝑗 = 1,2,3; 𝑡 = 1, … , 15, 
where 𝑋𝑖𝑗𝑡 is a vector of variables representing the alternative specific constant (ASC) and 
attributes of alternative 𝑗, and 𝛽𝑖 is a vector of random coefficients assumed to be 
uncorrelated and normally distributed except for the coefficients of the cost and effectiveness 
attributes, which were assumed to be distributed log-normally. The ASC represents 
preferences that are inherent and independent of specific attribute values. A positive 
coefficient of the level within the attribute indicates a stronger preference compared to the 
reference group and a negative coefficient denotes a stronger preference for the reference. 
The cost attribute was entered into the model in its negative form. The errors 𝜀𝑖𝑗𝑡 were 
independently and identically distributed as a type 1 extreme value. 
The willingness to pay (WTP) distributions were simulated using the ratio of random 
coefficients (with the coefficient of the cost attribute as the denominator). The mean WTPs 
and percentiles were then estimated using the random draws from the simulated distributions. 
In the calculation, we accounted for parameter uncertainty by using all information in the 
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parameter distribution including the covariance matrix rather than just the mean and standard 
deviation. As noted by Hensher and Greene [28] in 2003, this is preferred because using just 
the mean and standard deviation ignores the sampling variance in the point estimates. 
To determine whether the respondents’ characteristics impacted their preferences, dummy 
variables representing individual characteristics were interacted with the preference 
coefficients at their means. This essentially split the sample into two groups with group-
specific mean preferences to be estimated. The statistical significance of the coefficients of 
the interaction terms was used to test the preference homogeneity assumption between two 
groups.  
Statistical analyses were conducted with STATA 14 (StataCorp, College Station, TX, USA). 
The mixed logit models were estimated by the simulated maximum likelihood using the 
STATA command developed by Hole [29]. In total, 2,000 Halton draws were used to 
simulate the likelihood. 
 
Results 
A total of 282 patients returned the questionnaire. The patients’ characteristics are 
summarized in Table 2. More than four-fifths were women, around 40% of the population 
reported that they were diagnosed with osteoporosis, and one-fifth had a history of fracture. 
The mean age of the population was 63.4 years (SD, 10.2 years), most patients had a normal 
weight (average body mass index [BMI], 22.6 kg/m2), and the mean T-score of the 
population was −2.1 (SD, 0.8). Approximately 11% of the population had no school 
education, and 14% had a university education or above. On average, 2.3 adults were living 
in each household, and an annual per-adult income of 50,000 Yuan roughly separated the 
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households in half. One patient rated easiest (0) and 6 patients rated hardest (10) for the 
difficulty of DCE. On average, the patients scored 5.7 (SD, 2.0, median, 6) indicating that the 
DCE tended to be moderately difficult for patients to complete.  
<Table 2 should be inserted here> 
Fifteen patients were unwilling to participate in the DCE and always opted out from the 
choices; hence, they were removed from the final analysis. Therefore, 267 (94.7%) patients 
were included in the final analysis of medication preferences. The patients’ preferences for 
the attributes of osteoporosis pharmaceutical treatments are shown in Table 3. The mean ASC 
was 9.57, which indicated that on average, patients preferred to receive treatment than no 
treatment. In addition, the SD of the constant was statistically significant, indicating the 
presence of significant preference heterogeneity for treatment in this population. With respect 
to adverse effects of medication, the patients generally preferred being at risk for flu-like 
symptoms and skin reactions compared with gastrointestinal (GI) disorders. The preference 
was statistically significant. There was no statistically significant preference heterogeneity for 
adverse effects. Using a daily oral tablet as the reference for the mode of administration, the 
patients’ preferences for the other four modes of administration were assessed. Notably, the 
patients’ preference for yearly intravenous infusion was the strongest, followed by 6-month 
subcutaneous injections, weekly oral tablets, and daily nasal spray. In addition, patients 
significantly preferred yearly intravenous infusion and 6-month subcutaneous injection 
compared with weekly oral tablets. With the exception of weekly oral tablets, statistically 
significant preference heterogeneity was present for other three modes of administration, 
especially for yearly intravenous infusion. In addition, the patients significantly preferred 
medications with higher clinical efficacy and lower OOP cost.  
<Table 3 should be inserted here> 
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Table 4 shows patients’ WTP for attributes in the DCE. Using GI disorders as the reference, 
the patients were willing to pay 3,712 Yuan (the 5th and 95th percentiles: 875 and 7,121 Yuan, 
respectively) and 5,650 Yuan (5th and 95th percentiles: 2,714 and 9,445 Yuan, respectively) 
more per annum for treatment with flu-like symptoms and skin reactions, respectively. With 
respect to the mode of administration, patients were willing to pay 5,576 Yuan (5th and 95th 
percentiles: 2,190 and 10,133 Yuan, respectively), 26,395 Yuan (5th and 95th percentiles: 
17,005 and 39,261 Yuan, respectively), 30,884 Yuan (5th and 95th percentiles: 19,435 and 
46,808 Yuan, respectively), and 15,837 Yuan (5th and 95th percentiles: 10,067 and 23,730 
Yuan, respectively) more per annum if they could choose daily nasal spray, 6-month 
subcutaneous injection, yearly intravenous infusion, and weekly oral tablets over daily oral 
tablets. In addition, patients were willing to pay 3,689 Yuan (5th and 95th percentiles: 2,037 
and 6,532 Yuan, respectively) more per annum for a 1% improvement in medication efficacy 
of preventing fractures.  
<Table 4 should be inserted here> 
Patient age was found to be a main contributor to the heterogeneity of preferences (Table 5). 
Patients aged ≤60 years showed a statistically significant difference in their preference for 
adverse effects, while those aged >60 years did not. Moreover, the preference for skin 
reactions over GI disorders was significantly profound in young patients. While both age 
groups showed statistically significant differences in their preference for most of the modes 
of administration, the preference was stronger in patients aged ≤60 years, and the between-
group difference was statistically significant for daily nasal spray, 6-month subcutaneous 
injection, and yearly intravenous infusion. Similarly, patients aged ≤60 years also showed a 
stronger preference for lower OOP cost and higher clinical efficacy than their older 
counterparts.  
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<Table 5 should be inserted here> 
We further investigated whether sex, BMI, education, per-adult household income, a history 
of fracture, the visual analogue scale (VAS) score, and a self-reported diagnosis of 
osteoporosis contributed to between-group differences in preferences. The detailed results are 
provided in Appendix 1. Patients who were women, those with a non-healthy BMI, those 
with a school education of senior high school or above, and those with osteoporosis had a 
stronger preference (p<0.05) for receiving osteoporosis medication (Appendix Tables 1, 2, 3, 
and 7). Interestingly, despite the fact that 6-month subcutaneous injection was preferred over 
daily oral tablets, the preference was significantly stronger (p<0.05) in men (Appendix Table 
1), those with a junior high school education or lower (Appendix Table 3), and those with a 
VAS score of ≤60 (Appendix Table 6). In addition, patients with a history of fracture had a 
significantly stronger preference (p<0.05) for weekly oral tablets, but the preference for other 
modes of administration was not statistically stronger than that in patients with no previous 
fracture (Appendix Table 5). Finally, household income did not contribute to the 
heterogeneity of medication preference (Appendix Table 4).  
 
Discussion 
This study was performed to estimate Chinese patients’ preferences for osteoporosis 
medications using a DCE. Chinese patients preferred being at risk of skin reactions over flu-
like symptoms and GI disorders. Yearly intravenous infusion and 6-month subcutaneous 
injection were significantly preferred over weekly oral tablets, daily nasal spray, and daily 
oral tablets. Moreover, Chinese patients preferred a medication with a lower OOP cost and 
higher clinical efficacy. Patient characteristics including age, sex, level of education, self-
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reported VAS score, and previous fracture status contributed to the heterogeneity of 
preferences for osteoporosis medications.   
Our study reports, for the first time, Chinese patients’ preference for osteoporosis 
medications and we have investigated the preference orderings as well as patients’ WTP to 
trade between attributes in the DCE; Second, we have attempted to investigate the impact of 
covariates (e.g. age, sex, education level etc.) on individual preferences; Finally, our study 
results are helpful to HTA bodies or health policy decision makers when they make 
reimbursement decision on osteoporosis medications. It is broadly accepted that there is value 
in using patient preferences to inform HTA assessment and medication reimbursement 
decision making [30-32]. At the moment, many osteoporosis medications that demonstrate 
good clinical efficacy are still not publicly funded in China, such as denosumab [33]. On the 
other hand, many medications that are shown to be less clinically effective or poorer safety 
profile are still being used as first line treatment for osteoporosis in China, such as calcitonin 
[19]. Due to the financial barrier to patients, doctors are more likely to choose osteoporosis 
medications that are publicly funded. As a consequence, Chinese access to medications with 
higher clinical efficacy in preventing fracture and strong patient preference is limited.  Our 
study results will be helpful when seeking reimbursement for such medications from Chinese 
health policy decision making bodies. 
In a previous review of patient preferences for osteoporosis drug treatment, medication 
effectiveness was listed as the most important attribute of osteoporosis medications in many 
populations [34]. In the present study, patients also preferred medications with higher clinical 
efficacy/effectiveness of reducing fracture risk: patients were willing to pay 3,689 Yuan for a 
1% increase in medication efficacy. If a medication could further reduce the fracture risk by 
10%, the WTP was higher than any of the trade-offs among levels in other attributes (Table 
4). The medication dosing frequency has been found to be an important attribute that 
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influences patient behaviour. Chinese patients tended to prefer osteoporosis medications with 
a longer dosing frequency, which is consistent with other populations [35]. The preference 
for a longer dosing frequency is explained by medication convenience and ease of following 
a treatment regimen for a long time [36]. Not surprisingly, GI disorders were less preferred 
than flu-like symptoms and skin reactions and it was chosen as the reference. In addition, 
there was no heterogeneity in the preference for flu-like symptoms and skin reactions among 
the study population. GI disorders were related to the choice of treatment, and having a GI 
event was associated with reduced patient compliance to osteoporosis treatment [37].   
A better understanding of patients’ preferences might improve medication persistence and 
adherence, in turn improving the clinical and economic outcomes [4]. The current study 
followed the design of a study of patients’ preference for osteoporosis treatments among 
seven European countries [11]. Regarding the mode of administration, 6-month subcutaneous 
injection was the most preferred mode in Belgium, Switzerland, Spain, and the United 
Kingdom. Monthly oral tablets was the most preferred mode in France and the Netherlands. 
Interestingly, yearly intravenous infusion was the most preferred mode only in Ireland in this 
European study [11], and it was the most preferred mode in our Chinese population. Yearly 
intravenous infusion and 6-month subcutaneous injection were consistently preferred over 
weekly oral tablets in both European and Chinese populations. In addition, GI disorders were 
the least preferred adverse effect in all European populations [15] and our Chinese 
population. The differences in patients’ preferences for osteoporosis medications across these 
European and Chinese populations might be useful to pharmaceutical companies when they 
determine the formulation of their osteoporosis medications.   
This study has some limitations. First, the attributes and levels used in our DCE were taken 
from a European study instead of from interviews with local patients [38]. Although the 
similarities in the design between the Chinese and European studies makes the results 
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comparable, we might have missed some attributes that were important to the Chinese 
population. However, we consulted several local clinicians in our research team to verify 
attributes for a remedy. Second, we have only included three side effects while others such as 
osteonecrosis of the jaw (ONJ) and atypical femoral fractures might also make patients afraid 
of taking osteoporosis medications.  Nevertheless, incidence of ONJ is limited and highest in 
patients with malignancy receiving high doses of intravenous bisphosphonates and 
denosumab and it is not common in our study population [39]. Third, the a priori information 
used to develop the choice set was derived from a European study [11]. Although the same a 
priori distribution used in both studies made the results comparable, a more efficient design 
might be helpful to improve the precision of the estimated choice model parameters [40]. 
Fourth, this study involved a small sample of a population in China from one centre only and 
only one fifth of the study population were men. Consequently, the results might not be 
applicable to the entire Chinese population. Nevertheless, it is the first endeavour to elicit 
patient preferences for osteoporosis treatments in China. Future studies using a larger 
representative samples from China would be useful for comparison. Finally, one caveat must 
be raised for the interpretation of our study results. Although an understanding of patients’ 
preferences for medications might be helpful, it might not automatically lead to the 
improvement of medication adherence.  
 
Conclusion 
This is the first study to elicit Chinese patients’ preferences for osteoporosis medications and 
investigate patients’ characteristics that contribute to the heterogeneity of these preferences. 
The study results are useful to clinicians with respect to informing their prescribing 
behaviours in osteoporosis medications, and the better understanding of patients’ preferences 
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provided by this study is paramount for new drug development. The results could also be 
helpful to HTA bodies or health policy decision makers when they make reimbursement 
decision on osteoporosis medications. 
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Table 1. Attributes and levels in the discrete choice experiment 
Treatment efficacy in reducing the risk of fracture  20% 
 30% 
 40% 
 50% 
Out-of-pocket cost per year, RMB Yuana 520 
 2,600 
 4,160 
 5,200 
 26,000 
Adverse effects of treatmentb Flu-like symptoms 
 Skin reactions 
 Gastrointestinal disorders 
Mode of administration Daily oral tablet 
 Daily nasal spray 
 6-month subcutaneous injection 
 Yearly intravenous infusion 
 Weekly oral tablet 
a1 RMB Yuan = 0.15 US dollars in 2018. 
bAdverse effects of treatment were assumed to occur in 1 of every 50 patients undergoing 
treatment. Each of these adverse effects was relatively mild, disappeared after a few days, 
and had no long-term or severe consequences. 
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Table 2. Characteristics of participants 
 N = 282 
Number of women  228 
Age, years 63.4 (10.2) 
BMI, kg/m2 22.6 (3.4) 
Education  
  No school education 31 (11.1%) 
  Primary school 65 (23.3%) 
  Junior high school 68 (24.4%) 
  Senior high school or equivalent 76 (27.2%) 
  University education or above 39 (14.0%) 
Household income per annum, RMB Yuan 51,353 (52,874) 
  Per adult household income of <50,000 Yuan 151 (53.6%) 
  Per adult household income of ≥50,000 Yuan 131 (46.4%) 
Number of patients with previous fracture  66  
Number of patients with self-reported 
osteoporosis  
119 
  Years since self-reported diagnosis 2.9 (3.0) 
Bone mineral density, T-score -2.1 (0.8) 
Number of patients with osteoporosis defined by 
T-score  
88 
VAS score 68.5 (16.5) 
Difficulty scorea 5.7 (2.0) 
Data are presented as mean (SD) or n (%). 
BMI, body mass index; VAS, visual analogue scale. 
aDifficulty was evaluated on a 0- to 10-point scale, where 0 indicated easiest and 10 indicated 
hardest. 
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Table 3. Patients’ preferences for osteoporosis pharmaceutical treatments 
 
Mean of 
coefficient 
95% CI 
SD of 
coefficient 
95% CI 
ASC 9.57 7.51, 11.63 6.06 4.80, 7.33 
Adverse effects      
  Gastro-intestinal disorders Reference group 
  Flu like symptoms 0.24 0.06, 0.42 0.26 -0.01, 0.53 
  Skin reactions 0.38 0.19, 0.55 0.25 -0.11, 0.62 
Mode of administration     
  Daily oral tablet   Reference group 
  Daily nasal spray  0.36 0.15, 0.57 0.51 0.18, 0.85 
  6-months subcutaneous 
injection 
1.71 1.41, 1.99 1.16 0.87, 1.46 
  Yearly intravenous infusion 2.00 1.57, 2.42 1.99 1.54, 2.43 
  Weekly oral tablet 1.02 0.87, 1.23 0.02 -0.30, 0.33 
Clinical efficacy a 0.23 0.17, 0.30 1.32 0.39, 2.25 
OOP cost b -1.03 -1.27, -0.79 3.96 2.33, 5.58 
ASC, alternative specific constant; SD, standard deviation; CI, confidence interval; OOP, 
out-of-pocket 
aPreference was measured based on a 1% increase in medication efficacy of fracture 
prevention. 
bPreference was measured based on a 1,000-Yuan increase in OOP payment. 1 RMB Yuan = 
0.15 US dollars in 2018. 
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Table 4. Patients’ willingness to paya for attributions in the discrete choice experiment 
 Mean of coefficient 5th and 95th percentiles 
Adverse effects    
  Gastro-intestinal disorders Reference group 
  Flu like symptoms 3,712 875, 7,121 
  Skin reactions 5,650 2,714, 9,445 
Mode of administration   
  Daily oral tablet   Reference group 
  Daily nasal spray  5,576 2,190, 10,133 
  6-months subcutaneous injection 26,395 17,005, 39,261 
  Yearly intravenous infusion 30,884 19,435, 46,808 
  Weekly oral tablet 15,837 10,067, 23,730 
Clinical efficacy b 3,689 2,037, 6,532 
aWillingness to pay is presented in 2018 RMB Yuan per annum. 1 RMB Yuan = 0.15 US 
dollars in 2018. 
bWillingness to pay was measured based on a 1% increase in medication efficacy of fracture 
prevention. 
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Table 5. Differences in treatment preferences between patients aged ≤60 and >60 years 
 Mean of coefficient (95% CI) 
 ≤ 60 years  >60 years 
ASC 14.33 (11.10, 17.56) 12.37 (9.41, 15.32) 
Adverse effects    
  Gastro-intestinal disorders Reference group  
  Flu like symptoms 0.32 (0.00, 0.64) 0.07 (-0.23, 0.37) 
  Skin reactions 0.55 (0.24, 0.86) 0.10 (-0.17, 0.38) 
Mode of administration   
  Daily oral tablet   Reference group  
  Daily nasal spray  0.68 (0.32, 1.05) 0.11 (-0.17, 0.40) 
  6-month subcutaneous injection 2.30 (1.80, 2.81) 1.40 (0.98, 1.83) 
  Yearly intravenous infusion 2.78 (2.04, 3.51) 1.59 (1.06, 2.12) 
  Weekly oral tablet 1.08 (0.74, 1.42) 1.01 (0.75, 1.29) 
Clinical efficacy a 0.15 (0.10, 0.19) 0.10 (0.06, 0.14) 
OOP cost b -1.12 (-1.33, -0.90) -1.08 (-1.30, -0.86) 
Level in bold indicates that the between-group difference is statistically significant. 
ASC, alternative specific constant; CI, confidence interval; OOP, out-of-pocket 
aPreference was measured based on a 1% increase in medication efficacy of fracture 
prevention. 
bPreference was measured based on a 1,000-Yuan increase in OOP payment. 1 RMB Yuan = 
0.15 US dollars in 2018.  
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Figures 
 
 
Figure 1. A choice set in the discrete choice experiment. Patients were asked to choose 
between hypothetical Treatments A and B; they could also choose “No treatment” if they did 
not like any of the treatments. 1 RMB Yuan = 0.15 US dollars in 2018. 
 
 
